 Mustang Bio, Inc. Mustang MBIO, a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the European Medicines Agency EMA has granted Advanced Therapy Medicinal Product ATMP classification to MB-107, Mustangs lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency XSCID, also known as bubble boy disease. The U.S. Food and Drug Administration FDA previously granted Regenerative Medicine Advanced Therapy RMAT designation to MB-107 for the treatment of XSCID in August 2019. 